Drug Patents owned by Shionogi Inc

1. List of Fetroja drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9238657 SHIONOGI INC Cephalosporin having catechol group
Nov, 2033

(10 years from now)

US10004750 SHIONOGI INC Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof
Sep, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9949982 SHIONOGI INC Preparation containing cephalosporin having a catechol moiety
Sep, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 14, 2024
New Indication (I) Sep 25, 2023
Generating Antibiotic Incentives Now (GAIN) Nov 14, 2029

Drugs and Companies using CEFIDEROCOL SULFATE TOSYLATE ingredient

NCE-1 date: November, 2028

Market Authorisation Date: 14 November, 2019

Treatment: Method of treating bacterial infections

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

2. List of Mulpleta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7601746 SHIONOGI INC Compounds exhibiting thrombopoietin receptor agonism
Sep, 2024

(1 year, 7 months from now)

US8889722 SHIONOGI INC Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor
Jul, 2028

(5 years from now)

US8530668 SHIONOGI INC Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor
Jan, 2030

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9427402 SHIONOGI INC Preparation for improving solubility of poorly soluble drug
Sep, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 31, 2023

Drugs and Companies using LUSUTROMBOPAG ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 31 July, 2018

Treatment: Treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure

Dosage: TABLET;ORAL

More Information on Dosage

3. List of Ulesfia drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6793931 SHIONOGI INC Ectoparasite asphyxiator compositions and methods for their applications
Jul, 2022

(6 months ago)

US7294342 SHIONOGI INC Ectoparasite asphyxiator compositions and methods for their application
May, 2024

(1 year, 3 months from now)

Drugs and Companies using BENZYL ALCOHOL ingredient

Market Authorisation Date: 09 April, 2009

Treatment: Topical treatment of lice infestations

Dosage: LOTION;TOPICAL

How can I launch a generic of ULESFIA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic